Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics has demonstrated a solid upward trajectory in sales, achieving a 17% increase in nanochannel array flowcell sales in 2Q25 compared to the prior year, alongside a 7% increase in 3Q25. The company reported an 11% year-over-year increase in combined revenue from consumables, software, and other sources in 2Q25, with consumables and software revenues increasing by 16%. Furthermore, expectations for new optical genome mapping (OGM) installations have improved for FY2025, with projected installations rising to 20-25, up from the previous estimate of 15-20, indicating strong demand and potential for future growth in new and existing markets.

Bears say

Bionano Genomics faces several significant risks that contribute to a negative outlook on its stock, including potential lower-than-expected market uptake of its products and reduced utilization of its installed systems. Additionally, the company may struggle to secure necessary capital to fund operations, which raises concerns about financial sustainability and could result in dilution for existing shareholders. Given the projected sales per share and conservative valuation metrics, the financial outlook appears bleak amid these operational challenges.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.